Literature DB >> 27859664

Are deficits in cognition associated with psychotic-like experiences after cannabis?

Emma Barkus1, Paul Morrison2, Marta Di Forti2, Robin M Murray2.   

Abstract

Not all individuals who smoke cannabis report psychotic-like experiences. Given that risk factors for psychotic disorders are multifaceted, precipitating factors to psychotic-like experiences after cannabis are likely to be equally complex. Reduced neurocognitive performance is associated with both psychosis risk and cannabis use. Therefore, it is possible cognitive performance may differentiate those who report psychotic-like experiences after cannabis from those who do not. We determined whether those reporting psychotic/dysphoric experiences after cannabis had reduced neurocognitive performance compared to those reporting primarily euphoric experiences.
METHODS: Participants were recruited on the basis of responses to the cannabis high captured by the Psychosis-Dysphoric and Euphoric experiences subscales from the Cannabis Experiences Questionnaire (CEQ).
RESULTS: Compared to participants reporting primarily euphoric cannabis experiences (n = 36; 44% male; mean age (SD) = 28 (9) years), those who reported psychotic/dysphoric experiences (n = 40; 45% male; mean age (SD) = 26 (5) years) demonstrated significantly faster responses to a trial and error learning task. In the presence of distracters, those with psychotic/dysphoric experiences after cannabis made more errors on a Continuous Performance Task.
CONCLUSIONS: Those who report psychotic/dysphoric experiences after cannabis have subtle inefficiencies in their cognitive processes. The multiple factors which predict vulnerability to psychotic-like experiences after cannabis require further investigation.
Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  cannabis; cannabis experiences; cognition; schizotypy

Mesh:

Year:  2016        PMID: 27859664     DOI: 10.1002/hup.2556

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  3 in total

1.  Efficacy of a transdiagnostic, prevention-focused program for at-risk young adults: a waitlist-controlled trial.

Authors:  Nicole R DeTore; Lauren Luther; Wisteria Deng; Jordan Zimmerman; Logan Leathem; Anne S Burke; Maren B Nyer; Daphne J Holt
Journal:  Psychol Med       Date:  2022-03-01       Impact factor: 10.592

2.  Interactions Between Variation in Candidate Genes and Environmental Factors in the Etiology of Schizophrenia and Bipolar Disorder: a Systematic Review.

Authors:  Błażej Misiak; Filip Stramecki; Łukasz Gawęda; Katarzyna Prochwicz; Maria M Sąsiadek; Ahmed A Moustafa; Dorota Frydecka
Journal:  Mol Neurobiol       Date:  2017-08-18       Impact factor: 5.590

3.  Personality Traits and Psychotic Proneness Among Chronic Synthetic Cannabinoid Users.

Authors:  Koby Cohen; Shiri Rosenzweig; Paola Rosca; Albert Pinhasov; Abraham Weizman; Aviv Weinstein
Journal:  Front Psychiatry       Date:  2020-05-15       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.